Previously, we have demonstrated that Urolithin A mediated simultaneous targeting of the PI3K/Akt/mTOR pathway reduced PDAC tumor growth and improved survival in the genetically engineered mouse model (GEMM) of PDAC [15]. This evidence concerns the gene AKT1 and neoplasm.